Valeant Pharmaceuticals International (VRX) Shares are Down -6.71%

Valeant Pharmaceuticals International (VRX) has risen sharply, recording gains of 30.97% in the past 4 weeks. However, the stock has corrected -6.71% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 31.14% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.99% and the 50-Day Moving Average is 16.91%.The 200 Day SMA reached 44.92%. Valeant Pharmaceuticals International, Inc. has dropped 0.31% during the last 3-month period . Year-to-Date the stock performance stands at -71.71%.


Valeant Pharmaceuticals International (NYSE:VRX): The stock opened in the green at $29.28 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $29.32 and a low of $28.03 for the day. The stock did not find buyers even at the lows and closed at $28.76 recording a loss of -1.24%. 19,162,985 shares exchanged hands during the trading day. The stock had closed at $29.12 in the previous days trading.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.